Advertisement

Dopaminerge Übertragung bei Gesunden und Schizophrenen

  • J. L. Martinot
  • M. L. Paillère-Martinot
  • J. F. Allilaire
  • C. Loc’h
  • M. H. Dao-Castellana
  • M. Basquin
  • Y. Lecrubier
Conference paper

Zusammenfassung

Die ursprüngliche dopaminerge Hypothese der Schizophrenie stützt sich vor allem auf
  • die Fähigkeit der Dopaminagonisten, psychotische Symptome zu produzieren (jedoch können auch andere Substanzen wie z. B. LSD oder Steroide zu psychotischen Episoden führen, obwohl sie nicht spezifisch und direkt mit dem dopaminergen System interagieren) und

  • die antipsychotische Wirksamkeit der Neuroleptika. Diese wiederum beruht auf der gemeinsamen Eigenschaft der Neuroleptika, Dopaminrezeptoren zu blockieren (Carlsson u. Lindqvist 1963) sowie auf dem Nachweis einer in vitro Korrelation zwischen der Affinität der Neuroleptika für D2-Rezeptoren und ihrer „antipsychotischen Potenz“ (Creese 1976).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Aubin F, Lecrubier Y, Boyer P (1991) Principal component analysis od the SANS. Biol Psychiatry 29: 393Google Scholar
  2. Bleuler E (1911) Dementia praecox oder Gruppe der Schizophrenien. In: Aschaffenburg G (Hrsg) Handbuch der Psychiatrie. Franz Deuticke, LeipzigGoogle Scholar
  3. Brockington I (1993) Schizophrenia: yesterday’s concept. In: Pichot P, Rein W (eds) The clinical approach in Psychiatry (Collection: Les empêcheurs de penser en rond). Synthélabo, Le Plessis-Robinson, pp 383–392Google Scholar
  4. Carlsson A, Lindqvist M (1963) Effect of chlorpromazine or haloperidol on formation of 3.methoxy.tyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol 20: 140–144CrossRefGoogle Scholar
  5. Carnoy P, Ravard S, Hery D, Tassin JP, Soubri P (1987) Apomorphine-induced operant deficits: a neuroleptic — sensitive but drug-and dose-dependent animal model of behavior. Psychiatr Psychobiol II /4: 266–273Google Scholar
  6. Creese I, Burt DR, Snyder SH (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192: 481–483PubMedCrossRefGoogle Scholar
  7. Davidson M, Davis KL (1988) A comparison of plasma homovanillic acid concentrations in schizophrenics and normal controls. Arch Gen Psychiatry 45: 561–563PubMedGoogle Scholar
  8. Deutch AY (1992) The regulation of subcortical dopamine systems by the prefrontal cortex: interaction of central dopamine systems and the pathogenesis of schizophrenia. J Neur Transm Supp1 36:61–89Google Scholar
  9. Farde L, Wiesel FA, Stone Elander S et al. (1990) D2 dopamine receptors in neurolepticnaive schizophrenic patients. Arch Gen Psychiatry 47:213–219PubMedGoogle Scholar
  10. Gerlach J, Luhdorf K (1975) The effect of L-Dopa on young patients with simple schizophrenia treated with neuroleptic drugs. Psychopharmacology 44: 105–110CrossRefGoogle Scholar
  11. Goldberg SC (1985) Negative and deficit symtoms in schizophrenia do respond to neuroleptics. Schiz Bull 11: 453–456Google Scholar
  12. Howard R, Cluckie A, Levy R (1993) Striatal D2 receptor binding in late paraphrenia. Lancet 342: 562PubMedCrossRefGoogle Scholar
  13. Kane JM, Mayerhoff D (1989) Do negative symptoms respond to pharmacological treatment? Br J Psychiatry 155 (suppl 7): 115–118Google Scholar
  14. Karlsson P, Farde L, Nordstrom AL, Sedvall G (1993) Dl-dopamine receptor binding in drug naive schizophrenic patients measured by PET. J Cereb Blood Flow Metab 13, suppl 1: 556Google Scholar
  15. Konig P, Benzer MK, Fritzsche H (1991) SPECT technique for visualization of cerebral dopamine D2 receptors. Am J Psychiatry 148: 1607–1608PubMedGoogle Scholar
  16. Kornhuber J, Riederer P, Reynolds GP et al. (1989) J Neur Transm 75: 1–10CrossRefGoogle Scholar
  17. Lamelle M, Casanova M, Weinberger DR, Kleinmann J (1990) Postmortem study of the dopaminergic D1 receptors in the dorsolateral prefrontal cortex of schizophrenics and controls. Schiz Res 3: 30CrossRefGoogle Scholar
  18. Liddle PF, Friston KJ, Frith CD, Hirsch SR, Jones T, Frackowiac RSJ (1992) Patterns of cerebral blood flow in schizophrenia. Br J Psychiatry 160: 179–186PubMedCrossRefGoogle Scholar
  19. Liddle PF (1987) The symptoms of chronic schizophrenia. Are-examination of the Positive-Negative dichotomy. Br J Psychiatry 151: 145–151PubMedCrossRefGoogle Scholar
  20. Martinot JL, Paillère-Martinot ML, Loch C et al. (1991) The D2 striatal receptor estimated density in schizophrenia. A study with PET and 76Br-Bromolisuride. Br J Psychiatry 158: 346–350PubMedCrossRefGoogle Scholar
  21. Martinot JL, Paillère-Martinot ML, Loc’h C et al. (to be published) Central D9 receptors and negative symptoms of schizophrenia. Br J PsychiatryGoogle Scholar
  22. Martinot JL, Peron-Magnan P, Huret JD et al. (1990) Striatal D2 dopaminergic receptors assessed by positron emission tomography and 76Br-bromospiperone in untreated schizophrenics. Am J Psychiatry 147: 44–50PubMedGoogle Scholar
  23. Meltzer HY, Sommers AA, Luchins DJ (1986) The effect of neuroleptics and other psychotropic drugs on negative symptoms in schizophrenia. J Clin Psychopharmacol 6: 329–338PubMedCrossRefGoogle Scholar
  24. Pickar D, Breier A, Hsiao JK, Doran AR, Wolkoitz OM, Pato CN, Potter WZ (1990) Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis. Arch Gen Psychiatry 47: 641–648PubMedGoogle Scholar
  25. Pickar D, Labarca R, Linnoila M, Roy A, Hommer D, Everett D, Paul SM (1984) Neuroleptic-induced decrease in plasma homovanilic acid in schizophrenic patients. Science 225: 954–957PubMedCrossRefGoogle Scholar
  26. Pilowski LS, Costa DC, EII PJ, Verhoeff NPLG, Murray RM, Kerwin RW (1993) D2 receptor abnormalities in schizophrenia: a 1231 IBZM single photon emission tomography study of drug naive schizophrenic patients. J Cereb Blood Flow Metab (Suppl 1 ) 13: 512Google Scholar
  27. Puech AJ, Simon P, Boissier JR (1978) Benzamides and classical neuroleptics. Comparison of their actions using 6-apomorphine-induced effects. Eur J Pharmacol 50: 291–300PubMedCrossRefGoogle Scholar
  28. Seeman P (1987) Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1: 133–152PubMedCrossRefGoogle Scholar
  29. Seeman P, Guan HC, Van Tol HM (1993) Dopamine D4 receptors elevated in schizophrenia. Nature 365: 441–445PubMedCrossRefGoogle Scholar
  30. Sokoloff P, Giros B, Martes MP, Bouthenet ML, Schwartz JC (1991) Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347: 146–151CrossRefGoogle Scholar
  31. Stoll AL, Tohen M, Baldessarini RJ et al. (1993) Shifts in diagnostic frequencies of schizophrenia and major affective disorders at six psychiatric hospitals, 1972–1988. Am J Psychiatry 150: 1668–1673PubMedGoogle Scholar
  32. Tassin JP (1992) NE/DA interactions in prefrontal cortex and their possible roles as neuro-modulators in schizophrenia. J Neur Transm Supp1 36:135–162Google Scholar
  33. Wong DF, Wagner HN, Tune LE et al. (1986) Positron emission tomography reveals el- evated D2 dopamine receptors in drug-naive shizophrenics. Science 234: 1558–1563PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1995

Authors and Affiliations

  • J. L. Martinot
  • M. L. Paillère-Martinot
  • J. F. Allilaire
  • C. Loc’h
  • M. H. Dao-Castellana
  • M. Basquin
  • Y. Lecrubier

There are no affiliations available

Personalised recommendations